Targeting BRCA1‐BER deficient breast cancer by ATM or DNA‐PKcs blockade either alone or in combination with cisplatin for personalized therapyNada Albarakati, Srinivasan Madhusudan, Emad A. Rakha et al.|Molecular Oncology|2014Cited by 80
Checkpoint kinase1 (CHK1) is an important biomarker in breast cancer having a role in chemotherapy responseMethaq Mueen Al-kaabi, Emad A. Rakha, Alaa T. Alshareeda et al.|British Journal of Cancer|2015Cited by 50
Chk1 phosphorylated at serine345 is a predictor of early local recurrence and radio‐resistance in breast cancerNouf H. Alsubhi, Srinivasan Madhusudan, Fiona K. Middleton et al.|Molecular Oncology|2015Cited by 42
Clinicopathological Significance of ATM-Chk2 Expression in Sporadic Breast Cancers: a Comprehensive Analysis in Large CohortsTarek M. Abdel-Fatah, Srinivasan Madhusudan, Arvind Arora et al.|Neoplasia|2014Cited by 41
Targeting ataxia telangiectasia-mutated- and Rad3-related kinase (ATR) in PTEN-deficient breast cancers for personalized therapyNouf H. Alsubhi, Srinivasan Madhusudan, Andrew R. Green et al.|Breast Cancer Research and Treatment|2018Cited by 30